There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

GSK filed suit in August 2023, alleging that Pfizer’s respiratory syncytial virus (“RSV”) vaccine, ABRYSVO, infringes four U.S. patents covering GSK’s rival RSV vaccine, AVREXY.

Symptomatic HSV-2 infection is also associated with an ... and therapeutics that reduce severity and viral load. Another company, GSK, completed a vaccine trial in September 2024, but the vaccine ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...

RSV vaccine Arexvy is likely to have a muted sales ramp in the near term. GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on ...

Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...